Compile Data Set for Download or QSAR
Report error Found 45 Enz. Inhib. hit(s) with all data for entry = 2946
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385987(US10287293, Example 36 | (R)- or (S)-5- (hydroxyme...)
Affinity DataKi:  0.400nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385981(US10287293, Example 30 | (R)- or (S)-7-(1-(2- fluo...)
Affinity DataKi:  0.800nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385968(US10287293, Example 17 | (R)- or (S)-3- (1-(3- Fl...)
Affinity DataKi:  0.900nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385968(US10287293, Example 17 | (R)- or (S)-3- (1-(3- Fl...)
Affinity DataKi:  1nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385985(US10287293, Example 34 | US10287293, Example 35 | ...)
Affinity DataKi:  1nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385958(US10287293, Example 7 | (R)- or (S)-3- (1-(3- Flu...)
Affinity DataKi:  1.10nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385983(US10287293, Example 32 | (R)- or (S)-5- (hydroxyme...)
Affinity DataKi:  1.20nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385979(US10287293, Example 28 | US10287293, Example 29)
Affinity DataKi:  1.20nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385966(US10287293, Example 15 | US10287293, Example 16 | ...)
Affinity DataKi:  1.30nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385954(US10287293, Example 3 | US10287293, Example 4)
Affinity DataKi:  1.70nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385991(US10287293, Example 40)
Affinity DataKi:  1.70nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385964(US10287293, Example 13 | US10287293, Example 14)
Affinity DataKi:  1.80nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385956(US10287293, Example 5 | (R)- or (S)-3-(1- (4-(ter...)
Affinity DataKi:  2.70nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385989(US10287293, Example 38)
Affinity DataKi:  6.10nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385962(US10287293, Example 11 | US10287293, Example 12)
Affinity DataKi:  6.30nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385974(US10287293, Example 23 | US10287293, Example 24)
Affinity DataKi:  6.70nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385962(US10287293, Example 11 | US10287293, Example 12)
Affinity DataKi:  7nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385952(US10287293, Example 1 | US10287293, Example 2)
Affinity DataKi:  15.2nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385972(US10287293, Example 21 | US10287293, Example 22)
Affinity DataKi:  15.6nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385977(US10287293, Example 26 | US10287293, Example 27)
Affinity DataKi:  17.2nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385952(US10287293, Example 1 | US10287293, Example 2)
Affinity DataKi:  17.8nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385977(US10287293, Example 26 | US10287293, Example 27)
Affinity DataKi:  21nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385968(US10287293, Example 17 | (R)- or (S)-3- (1-(3- Fl...)
Affinity DataKi:  24.5nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385964(US10287293, Example 13 | US10287293, Example 14)
Affinity DataKi:  26.8nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385958(US10287293, Example 7 | (R)- or (S)-3- (1-(3- Flu...)
Affinity DataKi:  32.1nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385976(US10287293, Example 25)
Affinity DataKi:  60.9nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385983(US10287293, Example 32 | (R)- or (S)-5- (hydroxyme...)
Affinity DataKi:  62.5nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385954(US10287293, Example 3 | US10287293, Example 4)
Affinity DataKi:  64.7nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385976(US10287293, Example 25)
Affinity DataKi:  70.3nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385966(US10287293, Example 15 | US10287293, Example 16 | ...)
Affinity DataKi:  82.9nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385990(US10287293, Example 39)
Affinity DataKi:  90.3nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385987(US10287293, Example 36 | (R)- or (S)-5- (hydroxyme...)
Affinity DataKi:  109nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385956(US10287293, Example 5 | (R)- or (S)-3-(1- (4-(ter...)
Affinity DataKi:  125nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385974(US10287293, Example 23 | US10287293, Example 24)
Affinity DataKi:  142nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385962(US10287293, Example 11 | US10287293, Example 12)
Affinity DataKi:  178nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385981(US10287293, Example 30 | (R)- or (S)-7-(1-(2- fluo...)
Affinity DataKi:  200nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385960(US10287293, Example 9 | US10287293, Example 10 | (...)
Affinity DataKi:  206nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385985(US10287293, Example 34 | US10287293, Example 35 | ...)
Affinity DataKi:  216nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385972(US10287293, Example 21 | US10287293, Example 22)
Affinity DataKi:  239nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385952(US10287293, Example 1 | US10287293, Example 2)
Affinity DataKi:  293nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385979(US10287293, Example 28 | US10287293, Example 29)
Affinity DataKi:  298nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385970(US10287293, Example 19 | US10287293, Example 20)
Affinity DataKi:  324nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385970(US10287293, Example 19 | US10287293, Example 20)
Affinity DataKi:  521nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetPhosphodiesterase(Rhesus macaque)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385977(US10287293, Example 26 | US10287293, Example 27)
Affinity DataKi:  779nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM385960(US10287293, Example 9 | US10287293, Example 10 | (...)
Affinity DataKi:  2.80E+3nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent